First Hormone Replacement Therapy for Hypoparathyroidism Receives FDA Priority Review
ADC评论
November 3, 2022
Ascendis Pharma announced that the FDA has accepted and granted Priority Review status for TransCon PTH for the treatment of adult patients with hypoparathyroidism, with
